Filing Flows › Stoke Therapeutics (STOK) › R&D spending
Stoke Therapeutics (STOK) R&D spending by quarter
Stoke Therapeutics' R&D spending was $59.8M in Q3 2026 (third quarter 2026), +21% from Q2 2026. Over the last 7 quarters it ranged from $25.9M (Q2 2025) to $59.8M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $59.8M | +21% | +59% |
| Q2 2026 | $49.5M | +25% | +91% |
| Q1 2026 | $39.7M | -5% | +21% |
| Q4 2025 | $41.7M | +11% | — |
| Q3 2025 | $37.7M | +46% | — |
| Q2 2025 | $25.9M | -21% | — |
| Q1 2025 | $32.7M | — | — |
Q3 2026 at a glance
Stoke Therapeutics, Q3 2026: revenue $11.3M (+6% year over year), operating margin -686.9%, net loss $73.6M, operating cash flow −$62.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Stoke Therapeutics' R&D spending?
Stoke Therapeutics' R&D spending was $59.8M in Q3 2026 (third quarter 2026), +21% from Q2 2026.
How has Stoke Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $25.9M (Q2 2025) to $59.8M (Q3 2026).